Prions are proteinaceous pathogens that cause a series of fatal encephalopathies such as human Creuzfeldt-Jakob disease, sheep scrapie and bovine spongiform encephalopathy [1, 2] . All prion diseases are characterized by the conversion of the constitutive cellular prion protein (PrP C ) into the pathogenic form, which is also known as scrapie PrP (PrP Sc ). This pathogenic form is believed to constitute the main component of the infectious transmissible spongiform encephalopathy (TSE) agent. All forms of prion disease are characterized by various neurological symptoms and common histopathological features such as spongiform degeneration of the central nervous system, reactive gliosis, neuronal loss and, in some cases, formation of amyloid plaques [3] .
The physiological function of the cellular prion protein is still unclear. It is mainly expressed on neurons and is evolutionarily highly conserved. As PrP C can bind Cu 2+ and may have some superoxide dismutase activity, it could have a possible protective function against oxidative stress [4−7] . Attempts at further insight into the putative function of PrP C have been made by searching for interacting proteins using various biophysical assays. Candidate proteins found are tau, apolipoprotein E (ApoE), tubulin, TREK-1 and the 37 kDa low density lipoprotein receptorrelated protein (LRP) [8−11] . Moreover, it has been suggested that PrP C plays a role in signal transduction, as cross-linking leads to activation of the tyrosine kinase Fyn that is involved in intracellular signaling [12] .
Protein kinase casein kinase II (CK2) is a serine/threonine kinase highly conserved in eukaryotic cells. It is a ubiquitously expressed and pleiotropic enzyme involved in the control of various cellular processes, such as cell cycle, apoptosis, transcriptional regulation, and signal transduction [13−16] . CK2 is much more abundant in the brain than in other tissues. In neural cells, there appears to be a myriad of CK2 substrates that have clear implications in neural development, neuritogenesis, synaptic transmission, and plasticity [17] . The CK2 holoenzyme is generally composed of two catalytic α or α' subunits and two regulatory β subunits and forms a tetrameric structure through the dimerization of the two β subunits. The α or α' subunits are catalytically active, whereas the β subunits are inactive but appear to modulate enzyme activity and substrate specificity by targeting the enzyme to its substrates [13, 15, 18] . In addition, evidence has indicated that the α and β subunits can exist in vivo and individually interact with other cellular proteins, implying that the CK2 subunits may have biological functions other than those assigned to the holoenzyme [19, 20] .
In neurodegenerative diseases, such as Alzheimer's disease, the amount and activity of CK2 are believed to be decreased [17, 21, 22] . Recently, we identified that, in the brains of hamsters or mice experimentally infected with scrapie and in cerebella homogenates, from one Creuzfeldt-Jakob disease case and one fatal familial insomnia (FFI) case, the contents of CK2α and CK2β decreased, while that of CK2α' or/and CK2α'' increased at the terminal stages [23] . The changes in CK2 level and pattern in scrapie-infected animals and naturally occurred human TSE indicate the potential linkage of CK2 and prion diseases.
In order to investigate whether there is molecular interaction between CK2 and PrP, human CK2α and CK2β complementary DNA (cDNA) were amplified. The fulllength human CK2α and CK2β, as well as various human PrP (huPrP) proteins, were expressed in the Escherichia coli (E. coli). Reliable evidence has demonstrated that recombinant PrP formed complex with CK2α, but not with CK2β. Moreover, the native CK2 and PrP C from normal hamster brains interacted with each other, forming protein complexes.
Materials and Methods
Cell culture and RNA extraction Human neuroblastoma cell line SH-SY5Y was maintained in Dulbecco's modified Eagle's medium (Gibco, Grand Island, USA) containing 10% fetal bovine serum. Total cellular RNA was extracted with a commercially supplied TRIzol agent (Invitrogen, Carsbad, USA) and stored at −70 ºC.
Plasmids construction
To obtain cDNA for human CK2 protein, 1 µg SH-SY5Y RNA was mixed with 5 U avian myeloblastosis virus reverse transcriptase (Invitrogen), 10 U RNAsin, 20 mM deoxyribonucleotide triphosphate and 20 pM oligo-dT in 20 µl volume at 37 ºC for 30 min. The product (2 µl) was mixed with 5 U Taq polymerase, 20 mM deoxyribonucleotide triphosphate and human CK2α or CK2β gene-specific primers for polymerase chain reaction (PCR). The primers of CK2α gene were P1: 5' -TAGGATCCATGAGCAGCTCAGAGGAGGT-3', with a BamHI digestion site in 5' terminus (underlined) and P2: 5'-ACAAGCTTTCAGCGAATCGTCTTGACTGG-3', with a HindIII cutting site in 5' terminus (underlined). The primers of CK2β gene were P1': 5'-TAGGATCCA-TGAGCAGCTCAGAGGAGGT-3', with a BamHI digestion site in 5' terminus (underlined) and P2' : 5 -C-AAAGCTTCATTACTGCTGAGCGCCAGCGGC-3, with a HindIII cutting site in 5' terminus (underlined). The PCR amplification conditions were 94 ºC for 30 s, 58 ºC for 30 s and 72 ºC for 60 s. The PCR products were ligated with commercially supplied T-vector (Promega, Madison, USA), generating plasmid pT-CK2α and pT-CK2β. After verification with sequence assay, the inserts of the CK2α and CK2β segments were released from pT-CK2α and pT-CK2β with BamHI and HindIII, and subcloned into expression vectors pET32a and pQE30-GST, respectively, generating recombinant plasmids pET32a-CK2α and pQE30-GST-CK2β.
Protein expression and purification
The CK2α or CK2β proteins, as well as the huPrP23-90, huPrP91-231 and huPrP23-231 proteins, were expressed in E. coli strains BL21/DE3, M15 or JM109 [9] . Briefly, transformed bacteria were grown to OD 600 of 0.5−0.6 and induced with 0.5 mM isopropyl-D-thiogalactoside at final concentration. Cells were harvested by centrifugation and resuspended in solution containing 1 mM EDTA, 300 mM NaCl and 30 mM Tris-Cl, pH 8.0, with 1 mM phenylmethylsulfonyl fluoride as protease inhibitor. Lysozyme was added to a 2 mg/ml final concentration, and cells were lysed by incubation for 30 min and additional sonication for 24×10 s with 10 s pauses at 400 W. Histidine (His)-tagged proteins were purified with Ni-NTA agarose (Qiagen, Bernd Uder, Germany), and glutathione S-transferase (GST)-fusion proteins were purified with Glutathione-Sepharose 4B (Amersham Pharmacia, Buckinghamshire,UK), according to the manufacturer's protocols. Protein concentrations were determined using a BCA kit (Qiagen). As we confirmed that the GST fusion tag would not influence the further experiments, including protein interaction [9, 10] , the GST-tag was not removed from the fusion proteins in this study.
Preparation of brain tissue homogenates
Normal hamsters' brain tissues (approved by the local ethics committee) were homogenized in 9 volumes (10%, W/V) of lysis buffer (100 mM NaCl, 10 mM ethylenediaminetetraacetic acid, 0.5% Nonidet P-40, 0.5% Sodium deoxycholate in 10 mM Tris-HCl, pH 7.4) [24] . The lysates were centrifuged at 20,000 g for 30 min and the supernatants were collected for further co-immunoprecipitation experiments.
Co-immunoprecipitation
We incubated 2 µM PrP23-231 with 2 µM CK2α or CK2β proteins in 500 µl binding buffer (50 mM Tris-HCl, 100 mM NaCl, pH 8.0), at 4 ºC for 2 h. After incubation with PrP-specific monoclonal antibody (mAb) 3F4 [Clone: 3F4(3); DakoCytomation, Glostrup, Danmark] for 2 h, 10 µl Protein G Sepharose (Roche, Basel, Switzerland) equilibrated by binding buffer was introduced into the reactions, and was vibrated while incubated for a further 2 h. The Sepharose beads were precipitated at 400 g for 5 min and washed with 500 µl washing buffer (50 mM Tris-Cl, 500 mM NaCl, pH 8.0) three times. Equal amounts of His-GST protein were employed as negative control. The bound complexes were separated by 15% sodium dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. The bound CK2α and CK2β proteins were detected by Western blot with anti-CK2α polyclonal antibody (pAb) (H-286; Santa Cruz, Santa Cruz, USA) or anti-CK2β specific antibodies (6D5; Santa Cruz).
To confirm a physiological interaction between native PrP C and native CK2α or CK2β proteins, anti-CK2α-or anti-CK2β-specific antibodies were incubated with 500 µl 10% homogenates prepared from normal hamster brains at 4 ºC for overnight. We introduced 10 µl Protein G Sepharose (Roche) equilibrated by binding buffer into the reactions, and it was incubated and vibrated for further 2 h. The Sepharose beads were precipitated at 400 g for 5 min and washed with 500 µl washing buffer (50 mM TrisCl, 500 mM NaCl, pH 8.0) three times. The bound complexes were separated by 15% SDS-PAGE and transferred to nitrocellulose membranes. The bound PrP was detected by Western blot 3F4 antibody.
His pull-down assay
To identify the interaction between recombinant full-length PrP (PrP23-231) and native CK2α from hamster brains, 2 µM PrP (containing His-tag) was incubated with 300 µl 10% homogenates from normal hamster brains in 500 µl binding solution containing 20 mM Tris-Cl, 200 mM NaCl, 10 mM aprotinin, pH 8.0, at 4 ºC for 3 h. Equal amounts of His-GST protein were used as negative control. We added 10 µl Ni-NTA agarose beads to the reaction solution and incubated at 37 ºC for 30 min with end-over-end mixing. After centrifugation at 400 g for 2 min at 4 ºC, the supernatants were discarded and beads were washed with 500 µl binding buffer three times for 5 min each time. The complexes were separated on 15% SDS-PAGE and transferred to nitrocellulose filter blocked with 5% nonfat milk in phosphate-buffered saline containing Tween-20. Using the enhanced chemiluminescence method (Perkin-Elmer, Boston, USA), we detected native CK2α protein with 1:4000 diluted anti-CK2α pAb as the primary antibody and 1:4000 diluted horseradish peroxidaseconjugated anti-rabbit immunoglobulin G as the secondary antibody.
Results

Expression of recombinant human CK2α and CK2β proteins
The total RNA extracted from SH-SY5Y cells was used in RT-PCR, and the PCR products, 1176 bp and 648 bp, were respectively amplified with human CK2α and CK2β primers. Sequencing analysis verified the PCR products were human CK2α and CK2β cDNA fragments (data not shown). To express the recombinant human CK2α and CK2β proteins in E. coli, the recombinant plasmids pET32a-CK2α and pQE30-GST-CK2β were separately transformed into E. coli strain BL21/DE3 and M15 cells. Using affinity chromatography of Ni-NTA agarose, a roughly 59 kDa His-CK2α fusion protein and a 54 kDa His-GST-CK2β fusion protein were purified from the cell lysates [ Fig. 1(A,B) ]. Western blot assays revealed that the 59 kDa band and 54 kDa band were specifically recognized by a anti-CK2α antibody or anti-CK2β antibody, respectively
With the same procedure, the full-length human PrP (His-PrP23-231) and the N-truncated human PrP protein (His-PrP91-231) were expressed and purified from E. coli [ Fig. 2(B) ]. Using affinity chromatography of Sepharose 4B, the C-truncated human PrP protein (GST-PrP23-90), mobilizing around 33 kDa in soluble form [ Fig. 2(B) ], was purified from the lysates of E. coli strain BL21/DE3 cells. Western blot analysis revealed that the purified PrP proteins could be recognized by PrP-specific antibody 3F4 (His-PrP23-231 and His-PrP91-231) or PrP-specific pAb FL-253 (GST-PrP23-90 fusion protein) [ Fig. 2(C) ].
Recombinant full-length PrP interacted with recombinant full-length CK2α, but not with CK2β in vitro To address the possible interaction between the full-length PrP and CK2 protein, the purified His-PrP23-231 fusion protein was mixed with CK2α protein in co-immunoprecipitation assays, while the mixture of His-GST protein and PrP was used as control. Firstly, the mixtures were captured by the anti-CK2α antibody, and the possibly bound PrP was detected with PrP-specific mAb 3F4 in Western blot; the anti-GST antibody was used as the capture antibody in the control. Western blots of the eluted (A), lane 4] . To confirm the observation in the co-immunoprecipitation assays, the mixture of His-PrP23-231 and CK2α were precipitated by PrP-specific 3F4 mAb, while anti-GST antibody was also used as the capture antibody in the control. Western blot of the eluted products with anti-CK2α pAb showed a reactive band in the reaction of His-PrP23-231 with CK2α [ Fig. 3(B), lanes 2 and 3] , but not in that of His-GST with CK2α [ Fig. 3(B), lane 6] . This suggests that recombinant full-length PrP and CK2α can interact and form complex in vitro.
To address whether the full-length PrP can interact with CK2β, the purified recombinant His-PrP23-231 and CK2β proteins were mixed in immunoprecipitation assay, while His-GST protein was used as control. After being precipitated with CK2β-or GST-specific antibodies, the bound PrP signals were illustrated in a PrP-specific Western blot. No PrP-specific reactive signal was detected either in the preparations of PrP23-231 and CK2β [ Fig. 3  (C), lane 2] , or in the preparations of PrP23-231 and His-GST [ Fig. 3(C) , lane 1], indicating that there was no molecular interaction between recombinant PrP and CK2β in vitro.
Native CK2α or PrP C from normal hamster brains interacted with the recombinant PrP or CK2α in vitro
To see whether native CK2 interacted with PrP, hamster brains were screened for the presence of CK2 subunits with Western blots. We prepared 10% homogenates from normal adult hamster brain tissue, which were separated on 15% SDS-PAGE. Western blots revealed clear CK2α-and CK2β-specific signals in brain tissue, which mobilized at positions 43 kDa and 28 kDa, respectively, as expected [ Fig. 4(A,B) ]. The purified His-PrP23-231 protein was further incubated with 10% brain homogenates, while His-GST protein was employed in parallel as control. The possible protein interactions were analyzed with His pull- products with 3F4 mAb demonstrated clear reactive bands in the preparation of His-PrP23-231 and CK2α [ Fig. 3  (A), lane 1] , whereas no reactive signal was observed in the preparation of His-PrP23-231 and His-GST [ Fig. 3 down assays. Western blot of the eluted product with anti-CK2α pAb demonstrated a specifically reactive band in the preparation of His-PrP23-231 and 10% brain homogenates [ Fig. 5(A), lane 3] , but not in that of His-GST and 10% brain homogenates [ Fig. 5(A), lane 2] . This demonstrates that the native CK2α in central nerve tissues can form a complex with recombinant full-length PrP in vitro.
To investigate the interaction between the native PrP C in brains with recombinant CK2α, 10% brain homogenates were mixed with the recombinant full-length His-CK2α fusion protein, and the protein interactions were evaluated in His pull-down assays. The eluted products were subsequently employed into PrP-specific Western blot with mAb 3F4. PrP-specific signal was detected in the reaction of brain homogenate with His-CK2α [ Fig. 5(B 
Native PrP C and CK2 formed protein-complex in normal brain homogenates
To further elucidate the possible interaction between native CK2 and native PrP in the central nerve tissues, 10% brain homogenates were incubated with anti-CK2α or anti-CK2β antibodies, and the bound PrP C were measured by PrP-specific Western blots. Three sharp PrP bands were seen in the preparation incubated with anti-CK2α antibody and with directly input PrP C , which were at positions from 25 to 35 kDa (Fig. 6, lanes 1 and 4) , but not in that incubated with GST antibody (Fig. 6, lane 3) . Interestingly, obviously weaker, but clear, PrP signals were also observed in the preparation precipitated with anti-CK2β antibody (Fig. 6, lane 2) . This suggests that native PrP and CK2 in brain homogenates can form protein complex each other.
The patterns of PrP specific bands in the preparation precipitated by anti-CK2α were quite different from those in the directly input one. In the latter, the signal of the The average values were calculated from three independent assays with a pool of brain homogenates from five normal hamsters and presented as mean±SD. The proportion of each profile in total is indicated on the top of each column as percentage. Native PrP is the data of the directly loaded 10% brain homogenates. CK2α-bound PrP is the data of 10% brain homogenates precipitated with CK2α-specific antibody. CK2, casein kinase II; mAb, monoclonal antibody; PrP, prion protein; PrP C , cellular PrP. smallest PrP C band representing aglycosal PrP C was much stronger (Fig. 6) . Analyses of the gray values of each PrP band showed that the proportion of aglycosal PrP C occupied about 42% of total PrP C precipitated by anti-CK2α, which was much higher than the proportion of aglycosal PrP C (19%) in the normal hamster brains. These data may indicate that within the three different glycosylated forms of PrP, the unglycosylated PrP has the stronger ability to form the CK2α-PrP complex.
The C-terminus of PrP [amino acids (aa) 91−231] was responsible for interacting with CK2α
To map the possible region within PrP interacting with CK2α, two truncated PrP, GST-PrP23-90 and His-PrP91-231, were employed into co-immunoprecipitation assays. After incubation with recombinant CK2α, the mixtures were precipitated with mAb 3F4 or anti-GST antibody and the bound CK2α was identified in the CK2α-specific Western blot analysis. As shown in the function of PrP C is still enigmatic. In the present study, co-immunoprecipitation and His pull-down assays provided direct evidence that both recombinant and native human PrP interact specifically with the catalytic subunit (CK2α) of protein kinase CK2. Previous studies have shown that the recombinant bovine PrP (rbPrP) can be phosphorylated by CK2 in vitro. The phosphorylating target is a seryl residue (Ser 154) sitting in a region predicted to change conformation during pathologic transition. When rbPrP is heated slowly to 82 ºC, the amount of phosphorylated rbPrP will double [25] . This implies that the ability of CK2 to impinge on rbPrP seems to depend on conformational features. Anpther investigation revealed that rbPrP can up-regulate the phosphorylation activity of CK2 [26] . These findings indicated that CK2 might interact with PrP and/or phosphorylate PrP, so as to promote or hinder PrP C -PrP Sc transition. We verified that the PrP region that interacts with CK2α is found at the C-terminal, spanning residues 91−231. PrP seems to interact, mostly at its N-terminal segment (aa 23−90) with many neuron proteins, including tau, ApoE, tubulin, GFAP, neural cell adhesion molecules, and MAP2 [8] [9] [10] [11] 27] . More recently, we confirmed that PrP can also bind to tubulin and GFAP; PrP's binding region with GFAP is located at its C-terminal segment (aa 91−231) [28, 29] . Active interactions of PrP with other proteins highlight its potential biological activities in many aspects. The region of PrP's C-terminal is of special importance because it encompasses the entire sequence of Proteinase K -resistant brain PrP Sc , contains all known point mutations associated with familial prion diseases and is sufficient for the propagation of those diseases. The C-terminal globular domain of PrP90-231 is comprised of three α-helices and two short β-strands. In prion diseases, the conformational conversion of PrP C to PrP Sc involves major refolding of the C-terminal α-helical region, accompanied by a marked increase in β-sheet structure [30−32] . Interactions with CK2α at this region indicate that CK2 plays a possible role in the conversion of PrP C to PrP Sc . CK2 is almost ubiquitous, but it is especially abundant in the brain [33−34] . It is therefore conceivable that PrP C and CK2 are given the opportunity to come into contact in the brain, especially considering that CK2 is one of the few protein kinases that may present on the outer leaflet of the plasma membrane, where PrP C also resides. In this same context it might be pertinent to recall that PrP C is found in caveolae, and that caveolin, the main constituent of caveolae, is both a target and an interacting partner of CK2 [35−36] . Although the majority of PrP are completely secreted into the endoplasmic reticulum lumen and at- 
Discussion
Several different screening methods have been previously used to identify proteins that interact with PrP C and/or PrP Sc . These assays have revealed some more-or-less well characterized binding partners for the PrP. Nevertheless, tached to the outer cell membrane via a glycosylphoshpatidylinositol anchor, transmembrane isoforms with either the N-terminus or the C-terminus in the endoplasmic reticulum lumen and the other end facing the cytosol have also been identified ( Ntm PrP and Ctm PrP, respectively). Ctm PrP represents a possible "loop-back" mechanism of the glycosylphoshp-atidylinositol-anchored form through the lipid bilayer.
Ctm PrP has been hypothesized to be a key pathogenic intermediate in both familial and infectiously acquired prion diseases [37−39] . Therefore, interaction of PrP C with proteins presenting in the cytosol is possible and the search for these proteins is feasible [12] . Although cytosol PrP ( Ctm PrP or Ntm PrP) is also present in a population of neurons in normal brains, the content of cytosol PrP in brains of TSE diseases increases [38] . Cytosol PrP do not undergo post-translational modification and most of them are non-glycosylated. We presume that the portion of non-glycosylated PrP might be the main component for binding with CK2α both in physiological and pathological status.
Moreover, we have found that three glycosylated forms of PrP, non-glycosylated, monoglycosylated and diglycosylated, seem to have significantly different abilities to interact with native CK2α in central nerve tissues. A comparative analysis of the PrP signal densities binding to CK2α demonstrates that the non-glycosylated PrP has a stronger ability to form the CK2α-PrP complexes. Previously we have described that, along with the remarkable increase in absolute amounts of all three PrP Sc isoforms in the hamster brains infected with scrapie strain 263K, the contents of monoglycosylated PrP and nonglycosylated PrP increase while that of diglycosylated PrP decreases [24] . Furthermore, the removal of glycosylation of prion protein can provoke cells apoptosis [40] . These findings imply that CK2 may have more opportunities to interact with the accumulated non-glycosylated PrP in TSE diseases at the terminal stages, which may contribute to the pathogenesis of prion diseases.
With recombinant proteins, PrP fails to form protein complex with CK2β. However, using anti-CK2β mAb, weak but clear PrP signals were observed in the hamster brain homogenate during co-immunoprecipitation. We speculate that it is not the presence of native PrP-CK2β complex in brain tissues. Since the native CK2 forms a tetrameric structure composed of two catalytic α-or α'-subunits and two regulatory β-subunits, the presence of PrP-specific signals in the preparation with anti-CK2β mAb may result from the interaction between the native PrP and CK2α subunits in CK2 and the subsequent precipitation by CK2β-specific antibody.
